FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283079524> ?p ?o ?g. }

• W4283079524 endingPage "756" @default.
• W4283079524 startingPage "749" @default.
• W4283079524 abstract "Abstract Background Venous thromboembolism (VTE) is a serious complication, particularly in cancer patients undergoing free flap reconstruction. Subcutaneous enoxaparin is the conventional prophylaxis for VTE prevention, and serum anti-factor Xa (afXa) levels are being increasingly used to monitor enoxaparin activity. In this study, free flap patients receiving standard enoxaparin prophylaxis were prospectively followed to investigate postoperative afXa levels and 90-day VTE and bleeding-related complications. Methods Patients undergoing free tissue transfer during an 8-month period were identified and prospectively followed. Patients received standard fixed enoxaparin dosing at 30 mg twice daily in head and neck (H&N) and 40 mg daily in breast reconstructions. Target peak prophylactic afXa range was 0.2 to 0.5 IU/mL. The primary outcome was the occurrence of 90-day postoperative VTE- and bleeding-related events. Independent predictors of afXa level and VTE incidence were analyzed for patients that met the inclusion criteria. Results Seventy-eight patients were prospectively followed. Four (5.1%) were diagnosed with VTE, and six (7.7%) experienced bleeding-related complications. The mean afXa levels in both VTE patients and bleeding patients were subprophylactic (0.13 ± 0.09 and 0.11 ± 0.07 IU/mL, respectively). Forty-six patients (21 breast, 25 H&N) had valid postoperative peak steady-state afXa levels. Among these, 15 (33%) patients achieved the target prophylactic range: 5 (33%) H&N and 10 (67%) breast patients. The mean afXa level for H&N patients was significantly lower than for breast patients (p = 0.0021). Patient total body weight was the sole negative predictor of afXa level (R 2 = 0.47, p < 0.0001). Conclusion Standard fixed enoxaparin dosing for postoperative VTE prophylaxis does not achieve target afXa levels for the majority of our free flap patients. H&N patients appear to be a particularly high-risk group that may require a more personalized and aggressive approach. Total body weight is the sole negative predictor of afXa level, supporting a role for weight-based enoxaparin dosing." @default.
• W4283079524 created "2022-06-19" @default.
• W4283079524 creator A5011043669 @default.
• W4283079524 creator A5013912685 @default.
• W4283079524 creator A5022897358 @default.
• W4283079524 creator A5023071200 @default.
• W4283079524 creator A5031747746 @default.
• W4283079524 creator A5034967803 @default.
• W4283079524 creator A5039207076 @default.
• W4283079524 creator A5043330559 @default.
• W4283079524 creator A5064112810 @default.
• W4283079524 creator A5065035277 @default.
• W4283079524 creator A5081996346 @default.
• W4283079524 date "2022-06-17" @default.
• W4283079524 modified "2023-10-11" @default.
• W4283079524 title "Standard Fixed Enoxaparin Dosing for Venous Thromboembolism Prophylaxis Leads to Low Peak Anti-Factor Xa Levels in Both Head and Neck and Breast Free Flap Patients" @default.
• W4283079524 cites W1626520712 @default.
• W4283079524 cites W1964926308 @default.
• W4283079524 cites W1967708854 @default.
• W4283079524 cites W1970350091 @default.
• W4283079524 cites W2048943006 @default.
• W4283079524 cites W2070825921 @default.
• W4283079524 cites W2075527927 @default.
• W4283079524 cites W2076506432 @default.
• W4283079524 cites W2083575074 @default.
• W4283079524 cites W2103154094 @default.
• W4283079524 cites W2106961808 @default.
• W4283079524 cites W2140254385 @default.
• W4283079524 cites W2162168177 @default.
• W4283079524 cites W2169109838 @default.
• W4283079524 cites W2175097202 @default.
• W4283079524 cites W2193655700 @default.
• W4283079524 cites W2286039737 @default.
• W4283079524 cites W2319742747 @default.
• W4283079524 cites W236013677 @default.
• W4283079524 cites W2462315700 @default.
• W4283079524 cites W2567397873 @default.
• W4283079524 cites W2572809378 @default.
• W4283079524 cites W2738176029 @default.
• W4283079524 cites W2757058403 @default.
• W4283079524 cites W2757637188 @default.
• W4283079524 cites W2758567736 @default.
• W4283079524 cites W2771562518 @default.
• W4283079524 cites W2774749322 @default.
• W4283079524 cites W2794717123 @default.
• W4283079524 cites W2796165711 @default.
• W4283079524 cites W2938408025 @default.
• W4283079524 cites W2944967372 @default.
• W4283079524 cites W2952859337 @default.
• W4283079524 cites W2970744313 @default.
• W4283079524 cites W2982664158 @default.
• W4283079524 cites W2984959088 @default.
• W4283079524 cites W3003100203 @default.
• W4283079524 cites W3004630456 @default.
• W4283079524 cites W3024351784 @default.
• W4283079524 cites W3032717486 @default.
• W4283079524 cites W3139193706 @default.
• W4283079524 cites W3162212716 @default.
• W4283079524 cites W4239960791 @default.
• W4283079524 cites W43892795 @default.
• W4283079524 doi "https://doi.org/10.1055/s-0042-1749340" @default.
• W4283079524 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35714620" @default.
• W4283079524 hasPublicationYear "2022" @default.
• W4283079524 type Work @default.
• W4283079524 citedByCount "6" @default.
• W4283079524 countsByYear W42830795242022 @default.
• W4283079524 countsByYear W42830795242023 @default.
• W4283079524 crossrefType "journal-article" @default.
• W4283079524 hasAuthorship W4283079524A5011043669 @default.
• W4283079524 hasAuthorship W4283079524A5013912685 @default.
• W4283079524 hasAuthorship W4283079524A5022897358 @default.
• W4283079524 hasAuthorship W4283079524A5023071200 @default.
• W4283079524 hasAuthorship W4283079524A5031747746 @default.
• W4283079524 hasAuthorship W4283079524A5034967803 @default.
• W4283079524 hasAuthorship W4283079524A5039207076 @default.
• W4283079524 hasAuthorship W4283079524A5043330559 @default.
• W4283079524 hasAuthorship W4283079524A5064112810 @default.
• W4283079524 hasAuthorship W4283079524A5065035277 @default.
• W4283079524 hasAuthorship W4283079524A5081996346 @default.
• W4283079524 hasConcept C120665830 @default.
• W4283079524 hasConcept C121332964 @default.
• W4283079524 hasConcept C121608353 @default.
• W4283079524 hasConcept C126322002 @default.
• W4283079524 hasConcept C141071460 @default.
• W4283079524 hasConcept C188816634 @default.
• W4283079524 hasConcept C2777288759 @default.
• W4283079524 hasConcept C2780868729 @default.
• W4283079524 hasConcept C2991741193 @default.
• W4283079524 hasConcept C42219234 @default.
• W4283079524 hasConcept C530470458 @default.
• W4283079524 hasConcept C61511704 @default.
• W4283079524 hasConcept C71924100 @default.
• W4283079524 hasConcept C81182388 @default.
• W4283079524 hasConceptScore W4283079524C120665830 @default.
• W4283079524 hasConceptScore W4283079524C121332964 @default.
• W4283079524 hasConceptScore W4283079524C121608353 @default.
• W4283079524 hasConceptScore W4283079524C126322002 @default.
• W4283079524 hasConceptScore W4283079524C141071460 @default.

• next